GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PTC Therapeutics Inc (FRA:BH3) » Definitions » EV-to-FCF

PTC Therapeutics (FRA:BH3) EV-to-FCF : -29.49 (As of Apr. 01, 2025)


View and export this data going back to 2013. Start your Free Trial

What is PTC Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, PTC Therapeutics's Enterprise Value is €4,942.1 Mil. PTC Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €-167.6 Mil. Therefore, PTC Therapeutics's EV-to-FCF for today is -29.49.

The historical rank and industry rank for PTC Therapeutics's EV-to-FCF or its related term are showing as below:

FRA:BH3' s EV-to-FCF Range Over the Past 10 Years
Min: -42.27   Med: -9.63   Max: 5270.68
Current: -30.83

During the past 13 years, the highest EV-to-FCF of PTC Therapeutics was 5270.68. The lowest was -42.27. And the median was -9.63.

FRA:BH3's EV-to-FCF is ranked worse than
100% of 433 companies
in the Biotechnology industry
Industry Median: 3.34 vs FRA:BH3: -30.83

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-01), PTC Therapeutics's stock price is €49.20. PTC Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-4.366. Therefore, PTC Therapeutics's PE Ratio (TTM) for today is At Loss.


PTC Therapeutics EV-to-FCF Historical Data

The historical data trend for PTC Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PTC Therapeutics EV-to-FCF Chart

PTC Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.28 -9.85 -7.54 -12.32 -26.60

PTC Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.32 -8.86 -7.19 -8.18 -26.60

Competitive Comparison of PTC Therapeutics's EV-to-FCF

For the Biotechnology subindustry, PTC Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PTC Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's EV-to-FCF falls into.


;
;

PTC Therapeutics EV-to-FCF Calculation

PTC Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=4942.101/-167.57
=-29.49

PTC Therapeutics's current Enterprise Value is €4,942.1 Mil.
PTC Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-167.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PTC Therapeutics  (FRA:BH3) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

PTC Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=49.20/-4.366
=At Loss

PTC Therapeutics's share price for today is €49.20.
PTC Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.366.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


PTC Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of PTC Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


PTC Therapeutics Business Description

Traded in Other Exchanges
Address
500 Warren Corporate Center Drive, Warren, NJ, USA, 07059
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

PTC Therapeutics Headlines

No Headlines